Latest Breaking News On - Lundbeckfonden biocapital - Page 1 : comparemela.com

Vesper Bio announces completion of single ascending dose stage in trial of its lead candidate VES001, a potentially disease-modifying treatment for fronto-temporal dementia

COPENHAGEN, Denmark, May 30, 2024 /PRNewswire/ Vesper Bio ApS ("Vesper" or "the Company"), a clinical stage biotech and world leader in sortilin receptor biology, today announces completion

IO Biotech, Inc. (NASDAQ:IOBT) most popular amongst private equity firms who own 61% of the shares, institutions hold 24%

Key Insights IO Biotech's significant private equity firms ownership suggests that the key decisions are influenced by.

Vesper Bio Doses First Volunteer In Phase I Study Of First-In-Class Oral Treatment For Frontotemporal ...

(MENAFN - PR Newswire) Vesper Bio, backed byLundbeckfonden BioCapital, initiates a Phase I study to evaluate its lead asset VES001, for the treatment of FTD (GRN mutation), addressing a critical . .

Vesper Bio doses first volunteer in Phase I study of first-in-class oral treatment for Frontotemporal Dementia (FTD)

NMD Pharma from Denmark secures €75M Series B to advance novel treatments for neuromuscular diseases